Patents Assigned to Minerva Biotechnologies Corporation
  • Agents for differentiating stem cells and treating cancer
    Patent number: 12202799
    Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: January 21, 2025
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Scott Moe
  • Method for making pluripotent stem cells
    Patent number: 12195728
    Abstract: The present application discloses a method for inducing cells to gain characteristics of naïve stem cell state comprising culturing the cells in the presence of a MUC1* activator.
    Type: Grant
    Filed: June 13, 2024
    Date of Patent: January 14, 2025
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: Cynthia Bamdad
  • Chimeric antigen receptor compositions and methods for treating MUC1* diseases
    Patent number: 12115192
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) that target MUC1*. In some embodiments, the CARs have been optimized to reduce T cell exhaustion.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: October 15, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Anti-NME antibody and method of treating cancer or cancer metastasis
    Patent number: 12049514
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: July 30, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Method for making pluripotent stem cells
    Patent number: 12049618
    Abstract: The present application discloses a method for inducing cells to gain characteristics of naïve stem cell state comprising culturing the cells in the presence of a MUC1* activator.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: July 30, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: Cynthia Bamdad
  • Anti-NME antibody and method of treating cancer or cancer metastasis
    Patent number: 12037413
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: July 16, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Humanized anti-MUC1* antibodies
    Patent number: 12006371
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: June 11, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Diagnostic methods using anti-MUC1* antibodies
    Patent number: 11976132
    Abstract: The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: May 7, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: Cynthia Bamdad
  • Media for stem cell proliferation and induction
    Patent number: 11976295
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Grant
    Filed: January 12, 2023
    Date of Patent: May 7, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Method of screening for agents for differentiating stem cells
    Patent number: 11931347
    Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: March 19, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Scott Moe
  • Humanized anti-MUC1* antibodies
    Patent number: 11897967
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: February 13, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Method for maintaining pluripotency in cells
    Patent number: 11898160
    Abstract: The present application describes a method for inducing or maintaining pluripotency in a cell by contacting the cell with a biological or chemical species that increases MUC1* activity.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: February 13, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia C. Bamdad, Shawn P. Fessler
  • Humanized anti-MUC1* antibodies
    Patent number: 11746159
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 5, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Method of treating an NME7 expressing cancer with a peptide
    Patent number: 11702483
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: July 18, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Media for stem cell proliferation and induction
    Patent number: 11591565
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: February 28, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • MUC1* antibodies
    Patent number: 11560435
    Abstract: The present describes monoclonal antibody to MUC1*.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: January 24, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Sanjeev Mahanta
  • ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASIS
    Publication number: 20220259324
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Application
    Filed: August 3, 2021
    Publication date: August 18, 2022
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • NME INHIBITORS AND METHODS OF USING NME INHIBITORS
    Publication number: 20220218846
    Abstract: The present application discloses inhibitors of NME family of proteins.
    Type: Application
    Filed: December 10, 2021
    Publication date: July 14, 2022
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia C. BAMDAD, Benoit SMAGGHE
  • METHODS FOR TREATMENT OF CANCER
    Publication number: 20220202786
    Abstract: A method for treating or preventing cancer in a subject comprising administering a treatment effective amount of a chemotype 4 compound.
    Type: Application
    Filed: November 17, 2021
    Publication date: June 30, 2022
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: Cynthia C. BAMDAD
  • NME INHIBITORS AND METHODS OF USING NME INHIBITORS
    Publication number: 20220089779
    Abstract: The present application discloses inhibitors of NME family of proteins.
    Type: Application
    Filed: May 3, 2021
    Publication date: March 24, 2022
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia BAMDAD, Benoit Smagghe